PASSAMONTI, FRANCESCO
PASSAMONTI, FRANCESCO
Dipartimento di Oncologia ed Emato-Oncologia
Characterization of a Newly Discovered Non‐Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis
2026 B. Mora, V. Bellani, D. Pietra, E. Tagliaferri, D. Cattaneo, O. Borsani, A. Iurlo, E. Fermo, P. Bianchi, E. Rumi, F. Passamonti
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026 L. Lanino, A.M. Hunter, N. Gagelmann, M. Robin, D. Dall'Olio, A. Flamigni, C. Sala, C. Gurnari, Y. Wang, L. Pleyer, B. Xicoy, G. Montalban-Bravo, L. Shih, A. Alsugair, S. Fathima, C. Gregorio, C. Rollo, L. Palomo, A.S. Platzbecker, G. Asti, R. Itzykson, D.A. Sallman, P. Fariselli, W. Kern, G. Garcia-Manero, U. Platzbecker, F. Solé, M. Diez-Campelo, J. Maciejewski, R. Bejar, F. Thol, N. Kroger, M. Savona, P. Fenaux, G. Sanz, S. Kordasti, V. Santini, M. Fontenay, A.M. Zeidan, R.S. Komrokji, T. Haferlach, U. Germing, G. Castellani, S. D'Amico, M. Patnaik, F. Ieva, E. Solary, A. Tefferi, E. Padron, M.G. Della Porta, N. Null, T. Haque, O. Abdel-Wahab, K. Geissler, A. Bataller, A. Bazinet, M. Meggendorfer, M. Quintavalla, A. Bruseghini, E. Sauta, L. Carota, T. Sanavia, L. Dall'Olio, E. Travaglino, L. Zamora, D. Quintela, A. Jerez, E. Cornejo, P. Garcia Martin, M. Diaz-Beya, A. Avendano Pita, V. Roldan, D.V. Fiallo Suárez, E. Cerezo Velasco, M. Calabuig, E. Such, C. Castilla-Llorente, C.E. Bulabois, L. Souchet, H. Awada, M. Bernardi, P. Chiusolo, A. Curti, L. Giaccone, C. Finelli, I. Casetti, F. Onida, L.M. Borin, M. Yung Follo, A. Consagra, F. Passamonti, E. Diral, V. Vucinic, G.M. Bergonzi, M.T. Voso, H. Hou, W. Chou, C. Yao, C. Lin, H. Tien, A. Campagna, M. Ubezio, A. Russo, G. Todisco, G. Maggioni, C.A. Tentori, A. Buizza, I. Ferrari, M. Di Matteo, A. Crespi, G. Figini, C. Delponte, F. Pesce, M. Zampini, E. Riva, M. Delleani, E. Iascone, L. Crisafulli, F. Ficara, D. Ventura, N. Pinocchio, M. Brindisi, A. Santoro, A. Kiwan, J. Vanoudenhove, N.H. Al Ali, T.A. Graubert, S. Thota, E. Griffiths
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis
2026 B. Mora, M. Franchi, L. Margotto, O. Leoni, D. D'Ippoliti, E. Carloni, I. Cozzi, E. Santelli, F. Gemmi, C. Szasz, M. Maffioli, C. Gurnari, E. Attardi, D. Cattaneo, M. Bortolotti, N.S. Fracchiolla, A. Iurlo, G. Corrao, M.G. Della Porta, A.M. Vannucchi, M.T. Voso, P. Guglielmelli, F. Passamonti
In silico-identified putative inhibitors of paraspeckle assembly induce cell death by apoptosis in Multiple Myeloma cells and lead to the activation of the cGAS/STING pathway.
2025 V. Traini, D. Ronchetti, G. Fabbiano, I. Silvestris, N. Puccio, F. Torricelli, V. Manicardi, M. Barbieri, F. Colombo, L. Porretti, Y. Torrente, I. Eberini, F. Passamonti, N. Bolli, A. Neri, E. Taiana
The biological relevance of upregulated NONO protein in multiple myeloma through the regulation of cell cycle progression and drug treatment response
2025 G. Fabbiano, V. Traini, I. Silvestris, D. Ronchetti, M. Barbieri, F. Lazzaroni, M. Scopetti, A. Matera, A. Maeda, F. Colombo, L. Porretti, F. Passamonti, N. Bolli, E. Taiana
Exploring the role of NONO in transcriptional regulation of cellular pathways in Multiple Myeloma: insights into its paraspeckle-dependent and independent regulatory mechanisms
2025 E. Taiana, A. Devecchi, I. Silvestris, V. Traini, G. Fabbiano, M. Lionetti, M.C. Da Vià, N. Puccio, I. Craparotta, M. Bolis, R. Piva, A. Neri, L. Agnelli, F. Passamonti, N. Bolli, D. Ronchetti
Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options
2025 A. Iurlo, D. Cattaneo, U. Gianelli, F. Passamonti
Exploring the role of NONO in transcriptional regulation of cellular pathways in Multiple Myeloma: insights into its paraspeckle-dependent and independent regulatory mechanisms
2025 E. Taiana, A. Devecchi, I. Silvestris, V. Traini, G. Fabbiano, M. Lionetti, M.C. Da Vià, N. Puccio, I. Craparotta, M. Bolis, R. Piva, A. Neri, L. Agnelli, F. Passamonti, N. Bolli, D. Ronchetti
Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes
2025 M. Lionetti, M. Scopetti, A. Matera, A. Maeda, A. Marella, F. Lazzaroni, G. Castellano, S. Fabris, S. Pioggia, S. Lonati, A. Marchetti, A. Cattaneo, M. Tornese, A. Neri, C. Leoni, L. Pettine, V. Traini, I. Silvestris, M. Barbieri, G. Fabbiano, D. Ronchetti, E. Taiana, C. De Magistris, M.C. Da Via', F. Passamonti, N. Bolli
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma
2025 M.C. Da Viá, F. Lazzaroni, A. Matera, A. Marella, A. Maeda, C. De Magistris, L. Pettine, A.G. Solimando, V. Desantis, G.M. Peretti, L. Mangiavini, R. Giorgino, S. Fabris, S. Pioggia, A. Marchetti, M. Barbieri, S. Lonati, A. Cattaneo, M. Tornese, M. Scopetti, E. Calvi, N. Latifinavid, G. Castellano, F. Torricelli, A. Neri, C. Fokkema, T. Cupedo, M. Lionetti, F. Passamonti, N. Bolli
Severe aplastic anemia secondary to immune checkpoint inhibitor: case report and literature review
2025 A. Bosi, M.C. Di Chio, M. Bortolotti, G.A. Croci, F. Passamonti, W. Barcellini, B. Fattizzo
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
2025 C. Papayannidis, E. Petracci, P. Zappasodi, N. Fracchiolla, F. Ciceri, C. Sartor, E. Roncoroni, F. Di Raimondo, D. Mattei, M.B. Giannini, F. Lanza, M. Gottardi, M.I. Del Principe, E. Borlenghi, M. Fumagalli, D. Vallisa, S. Sica, N. Di Renzo, F. Fabbiano, E. Todisco, P. de Fabritiis, M. Luppi, F. Passamonti, P. Corradini, F. Petruzziello, F. Pane, F. Ferrara, G. Mambelli, R. Volpi, F. Frabetti, C. Zingaretti, G. Marconi, G. Martinelli
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia
2025 A. Tefferi, S. Fathima, M. Abdelmagid, A. Alsugair, F. Aperna, M. Rezasoltani, M. Yousuf, A. Natu, C.M. Csizmar, M. Gurney, T.L. Lasho, C.M. Finke, R. Kanagal-Shamanna, D. Hammond, K.S. Chien, A. Bazinet, C.D. Dinardo, T.M. Kadia, A.A. Mangaonkar, N.G. Daver, A.D. Pardanani, G. Borthakur, C.J. Zepeda-Mendoza, K.K. Reichard, R. He, S. Loghavi, F. Passamonti, F. Ravandi, K. Sasaki, D. Larson, G. Garcia-Manero, F. Onida, N. Gangat, G. Montalban-Bravo, M.M. Patnaik
Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity
2025 P. Bono, A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, S. Allaria, C. Biassoni, G. Giacomel, A. Valzano, M. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri
Deciphering clinical features and treatment patterns of thrombocytopenic myelodysplastic syndromes
2025 N. Galli, L. Pettine, G. Croci, F. Passamonti, W. Barcellini, B. Fattizzo
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
2025 N. Polverelli, J.C. Hernández-Boluda, F. Onida, C. Gurnari, K. Raj, T. Czerw, M. Kenyon, M. Robin, K. Sockel, A. Ruggeri, I. Sánchez-Ortega, D.A. Arber, L. Arcaini, F.B. Duarte, G. Battipaglia, Y. Chalandon, F. Ciceri, N.C.P. Cross, J. Drozd-Sokolowska, V. Funke, N. Gagelmann, N. Gangat, J. Gotlib, P. Guglielmelli, C. Harrison, G. Hobbs, T. Jain, J.D. Khoury, J.J. Kiladjian, N. Kröger, L. Malcovati, M. Martino, R. Mesa, A. Orazi, E. Padron, F. Palandri, F. Passamonti, M.M. Patnaik, N. Pemmaraju, D.H. Radia, A. Reiter, D. Russo, C. Scheid, A. Tefferi, A.M. Vannucchi, D.H. Wiseman, I. Yakoub-Agha, D.P. Mclornan
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries
2025 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Corradini, P. Russo
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
2025 V. De Stefano, F. Passamonti, F. Palandri, F. Ramundo, E. Rossi, S. Betti, L. Fagiolo, P. Guglielmelli, D.P. Abagnale, N. Pugliese, D. Cattaneo, A. Iurlo, F. Branzanti, A. Dedola, H. Catellani, A. Tieghi, M. Basso, E. Calistri, E.M. Elli, E. Masselli, E. Morsia, G. Benevolo, M. Breccia, V. De Fazio, M. Di Perna, M. Marchetti, M. Santoro, A. Tafuri, C. Castiglioni, C. Rotella, S. Siragusa, A.M. Vannucchi, N. Null
The 2024 Three‐Strata Baseline Anemia Definition of the Revised IWG‐ELN Criteria Dissects Survival in Ruxolitinib‐Treated Myelofibrosis Patients
2025 M. Maffioli, B. Mora, A. Iurlo, E.M. Elli, M.C. Finazzi, M. Farina, E. Rumi, M. Caramella, M.C. Carraro, M. D'Adda, A. Molteni, E. Mimiola, F. Lunghi, A. Vismara, M. Ubezio, M.C. Di Chio, M. Anghilieri, D. Cattaneo, M.G. Della Porta, L. Bertù, M. Coscia, F. Passamonti
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries
2025 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Zinzani, P. Corradini, P. Russo